Michael Nissenblatt, MD
Medical Oncology · East Brunswick, NJNPI 1467441352
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,135 of the $15,078 with a category attached, or 87.1%. 20 manufacturers reported payments, led by AstraZeneca at 51.4% of the total. Reporting peaked in 2019 at $12,984 and has fallen 98.9% since, to $144 in 2025.
Across 46 payments — averaging $327.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Bayer$5K
- Daiichi Sankyo Inc.$579
- Athenex Pharmaceutical Division, LLC$325
- Novocure GmbH$200
- GSK$160
- plus $880 from 14 others
Across 3 payments — averaging $2783.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$8K
What the payments were for
- Consulting fees$6604%
- Speaking & faculty fees$13,13587%
- Travel & lodging$270%
- Food & beverage$1,1318%
- Education$1251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $7,749 |
| Bayer | 3 | $5,185 |
| Daiichi Sankyo Inc. | 6 | $579 |
| Athenex Pharmaceutical Division, LLC | 2 | $325 |
| Novocure GmbH | 1 | $200 |
| GSK | 1 | $160 |
| Karyopharm Therapeutics Inc. | 2 | $137 |
| Exelixis Inc. | 1 | $128 |
| Epizyme, Inc. | 1 | $125 |
| Comsort, Inc | 1 | $100 |
| Amgen | 1 | $90 |
| Regeneron Healthcare Solutions, Inc. | 3 | $63 |
| Novartis | 3 | $53 |
| Pfizer | 3 | $49 |
| Gilead | 2 | $36 |
| AbbVie | 2 | $35 |
| Astellas Pharma US Inc | 1 | $20 |
| Bristol Myers Squibb | 1 | $16 |
| Verastem, Inc. | 1 | $15 |
| Seagen Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$7,550
- Vitrakvi$5,185
- Enhertu$529
- Oral Paclitaxel$150
- Encequidar$150
- Cabometyx$128
- TAZVERIK$125
- XPOVIO$125
- KEYTRUDA$100
How this compares
$15,078 in reported general payments places this provider in the 75th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 27 | $437,350 |
| PomalystPomalidomide | 17 | $388,277 |
| OrserduElacestrant Hcl | 17 | $375,215 |
| CalquenceAcalabrutinib Maleate | 24 | $364,609 |
| XtandiEnzalutamide | 20 | $330,978 |
| Lenalidomide | 22 | $287,937 |
| TagrissoOsimertinib Mesylate | 15 | $237,049 |
| TruqapCapivasertib | 11 | $232,556 |
| RubracaRucaparib Camsylate | 11 | $197,184 |
| ImbruvicaIbrutinib | 11 | $175,849 |
| OpdivoNivolumab | 11 | $161,520 |
| KyprolisCarfilzomib | 18 | $152,333 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 12 | $151,715 |
| Somatuline DepotLanreotide Acetate | 15 | $140,867 |
| YonsaAbiraterone Acet,submicronized | 13 | $126,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso, Truqap | $7,749 | $834,21450 claims |
| Bristol Myers SquibbRevlimid | $16 | $437,35027 claims |
| Astellas Pharma US IncXtandi | $20 | $330,97820 claims |
| AmgenKyprolis, Aranesp | $90 | $209,92343 claims |
| PfizerEliquis, Nyvepria | $49 | $96,90184 claims |
| AbbVieLupron Depot, Restasis, Synthroid | $35 | $78,46347 claims |
| GSKTrelegy Ellipta | $160 | $7,27411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in East Brunswick
- Edward LicitraEast Brunswick$30K
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.